Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Biote Corp (BTMD)

Biote Corp (BTMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 115,527
  • Shares Outstanding, K 45,663
  • Annual Sales, $ 197,190 K
  • Annual Income, $ 3,160 K
  • EBIT $ 32 M
  • EBITDA $ 36 M
  • 60-Month Beta 1.16
  • Price/Sales 0.49
  • Price/Cash Flow 3.20
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.05
  • Number of Estimates 2
  • High Estimate 0.06
  • Low Estimate 0.04
  • Prior Year 0.10
  • Growth Rate Est. (year over year) -50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.38 +8.63%
on 01/07/26
2.90 -11.03%
on 12/11/25
-0.14 (-5.15%)
since 12/09/25
3-Month
2.32 +11.45%
on 11/20/25
3.26 -20.86%
on 10/22/25
-0.28 (-9.79%)
since 10/09/25
52-Week
2.32 +11.45%
on 11/20/25
6.03 -57.21%
on 01/16/25
-3.31 (-56.20%)
since 01/08/25

Most Recent Stories

More News
Biote Reports Third Quarter 2025 Financial Results

Continued progress against strategic priorities Repurchased approximately one million shares of Class A common stock Reiterates 2025...

BTMD : 2.58 (+1.98%)
Biote Schedules Third Quarter 2025 Financial Results Release and Conference Call

biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness,...

BTMD : 2.58 (+1.98%)
Biote Reports Second Quarter 2025 Financial Results

Q2 financial performance driven by strong dietary supplement sales and gross margin expansion Launched corporate reorganization to increase...

BTMD : 2.58 (+1.98%)
Biote Schedules Second Quarter 2025 Financial Results Release and Conference Call

biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness,...

BTMD : 2.58 (+1.98%)
Biote Schedules First Quarter 2023 Financial Results Release and Conference Call

biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading provider of preventive health care through the delivery of personalized hormone therapy, today announced the Company will provide...

BTMD : 2.58 (+1.98%)
Biote Names John Denne as General Manager, Men’s Health Division

Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced that John Denne has joined the Company as General Manager,...

BTMD : 2.58 (+1.98%)
Biote Reports Fourth Quarter and Full Year 2022 Financial Results

Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced financial results for the fourth quarter and full year...

BTMD : 2.58 (+1.98%)
Study: Testosterone Pellet Therapy Significantly Improves Bone Density in Male Patient Case Report

In a case study, a 54-year-old male patient with a spontaneous fracture and osteoporosis achieved an “almost complete recovery of osteoporosis” after one year of pelleted testosterone therapy and experienced...

BTMD : 2.58 (+1.98%)
Biote to Present at 35th Annual Roth Conference

biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading innovator in preventive health care through the delivery of personalized hormone therapy, today announced its participation in...

BTMD : 2.58 (+1.98%)
Biote Schedules Fourth Quarter and Full Year 2022 Financial Results Release and Conference Call

Biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading provider of preventive health care through the delivery of personalized hormone therapy, today announced the Company will provide...

BTMD : 2.58 (+1.98%)

Business Summary

BioTE Holdings, LLC is a medical practice-building business within the hormone optimization space. BioTE Holdings, LLC, formerly known as Haymaker Acquisition Corp. III, is based in NEW YORK.

See More

Key Turning Points

3rd Resistance Point 2.78
2nd Resistance Point 2.73
1st Resistance Point 2.65
Last Price 2.58
1st Support Level 2.53
2nd Support Level 2.48
3rd Support Level 2.40

See More

52-Week High 6.03
Fibonacci 61.8% 4.61
Fibonacci 50% 4.17
Fibonacci 38.2% 3.73
Last Price 2.58
52-Week Low 2.32

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar